Multiple-Scale Computational Studies of Redox-Controlled Supramolecular Co-Assembly Nanoplat form: Toward Immunochemotherapy-Driven Antitumor Augment
1. Abstract Programmed cell death protein 1 (PD1)/programmed death ligand 1 (PD-L1) blockades provide an effective and safe therapeutic option in the field of refractory cancer therapy. However, not more than 30% response rate of most cancers seriously impedes their therapeutic efficacy. Previous investigations have proved the effectiveness of combining chemotherapy with immunotherapy for unsatisfactory response to anti-PD1.